Core Viewpoint - Yuexiu Services (06626) anticipates a significant decline in profit for the fiscal year ending December 31, 2025, with a projected decrease of approximately 20% to 25% in profit attributable to equity holders compared to the fiscal year ending December 31, 2024, and a core net profit decline of about 45% to 50% [1] Financial Performance - The expected decline in profit and core net profit is primarily attributed to a decrease in gross margin [1] - Contributing factors include: 1. A reduction in high-margin value-added services, such as brokerage services, due to a deep adjustment in the real estate industry [1] 2. The completion of phase-based housing hard decoration projects, leading to decreased revenue and gross profit from this business [1] 3. Increased operational expenses due to ongoing investments aimed at enhancing service quality and stabilizing commercial project occupancy rates [1] 4. Rising labor costs resulting from policy adjustments [1] Future Outlook - For 2026, the company aims to pursue high-quality long-term growth and actively respond to industry adjustments [1] - The focus will be on scaling non-residential business and adjusting value-added services to cultivate profit growth points [1] - The company is committed to optimizing its structure and improving efficiency, moving towards its vision of becoming a "trusted smart city service provider" [1]

美团还表示，为了应对2025年度行业空前激烈的竞争，本集团已战略性地加大对整个生态体系的投入，以增强核心优势并推动可持续增 长。上述举措对核心本地商业分部2025年度的盈利能力造成了影响。 尽管受持续竞争影响，亏损趋势预计将在2026年第一季度延续， 但 截至本公告日期，本集团的经营状况维持稳健及正常，且本集团拥有充足的现金以支撑业务的稳健发展。 美团今日在港交所发布盈利预警公告称， 集团预期于截至2025年12月31日止年度（2025年度）录得亏损约人民币23,300百万元至人民 币24,300百万元， 相比之下，本集团于截至2024年12月31日止年度（2024年度）录得溢利约人民币35,808百万元。 对于2025年度的预期亏损原因，美团表示，主要是由于核心本地商业分部从2024年度约人民币52,415百万元的经营溢利转为2025年度约 人民币6,800百万元至人民币7,000百万元的经营亏损，同时本集团进一步加大了海外业务的投入。 往期推荐 多家银行，上调存款利率 来源：财联社 关注" 新华网财经 "视频号 更多财经资讯等你来看 雷军：春节期间小米汽车因自身故障抛锚，可报销1500元高铁/机票费和 5 ...

Core Viewpoint - The company, Meisi Health (02138), anticipates a decline in financial performance for the six months ending September 30, 2025, compared to the same period in 2024, with significant reductions in revenue, EBITDA, and net profit. Financial Performance Summary - Revenue is expected to decrease by no more than 10% compared to approximately HKD 2.063 billion for the six months ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% compared to approximately HKD 248 million for the same period [1] - Net profit is anticipated to drop by no more than 90% compared to approximately HKD 40.3 million for the six months ending September 30, 2024 [1] Reasons for Performance Decline - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China and increased outbound travel, has weakened local demand for discretionary medical and aesthetic services [1] - Several medical assets sold in the latter half of the previous fiscal year are no longer included in the financial statements, resulting in a lack of revenue contribution during the reporting period [1] - An unfavorable service mix with a decrease in the proportion of high-margin discretionary services [1] - Revenue decline has led to weakened operational leverage [1] Financial Position Summary - The company's overall asset and liability situation remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [2]

Core Viewpoint - The company, Meisi Health (02138.HK), anticipates a decline in financial performance for the six months ending September 30, 2025, based on preliminary unaudited consolidated management accounts Group 1: Financial Performance Expectations - Revenue for the reporting period is expected to decrease by no more than 10% compared to approximately HKD 2.063 billion for the corresponding period ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% compared to approximately HKD 247.9 million for the same period [1] - Net profit is anticipated to decrease by no more than 90% compared to approximately HKD 40.3 million for the corresponding period [1] Group 2: Reasons for Decline - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China and increased outbound travel, has weakened local demand for discretionary medical and aesthetic services [1] - Certain medical assets sold in the latter half of the previous fiscal year are no longer included in the financial statements, resulting in no revenue contribution for the reporting period [1] - A less favorable service mix with a decrease in the proportion of high-margin discretionary services [1] - Declining revenue has led to weakened operating leverage [1] Group 3: Financial Position - The overall asset-liability situation of the company remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [2]

Core Viewpoint - The company, 港仔机器人, has issued a profit warning indicating an expected increase in net losses for the upcoming interim period, primarily due to share-based payment expenses and losses from the sale of subsidiaries [1]. Financial Performance - The company anticipates a net loss attributable to shareholders of approximately HKD 59 million for the six months ending September 30, 2025, compared to a loss of about HKD 32.7 million for the same period in 2024 [1]. - The increase in losses is attributed to share-based payment expenses of approximately HKD 17.6 million and a net loss of about HKD 4.7 million from the sale of subsidiaries [1]. - After excluding the impact of share-based payments and subsidiary sales, the adjusted loss for the interim period is expected to be around HKD 36.7 million, a slight increase of approximately HKD 4 million compared to the previous year's adjusted loss of HKD 32.7 million [1]. Company Background - 港仔机器人集团控股有限公司 was established in Bermuda and listed in 1996, primarily engaged in international air and sea freight forwarding, logistics services, and trading of securities and commodities [1]. - The company has been expanding its financial services, including financing leasing in China since July 2015 and plans to develop its lending business in Hong Kong [1]. Stock Performance - The company has reported continuous losses since 2018, accumulating a total loss of HKD 740 million over seven years [2]. - The stock price has been on a downward trend since its second year of listing, reaching a record low of HKD 0.073 per share in September last year [2]. - Despite a brief surge in stock price to HKD 1.92 per share on June 9 this year, the upward momentum could not be sustained [2]. - As of November 20, the stock price has declined by 4.90%, trading at HKD 0.97 per share [3].

Core Viewpoint - ECI TECH (08013) anticipates a significant decline in net profit after tax for the fiscal year ending August 31, 2025, projecting a decrease of no less than 65% compared to the fiscal year ending August 31, 2024 [1] Financial Performance - The expected reduction in net profit is attributed primarily to the hiring of additional employees to support the company's expanding business operations [1]

Core Viewpoint - Changli Holdings (08098) anticipates a significant decrease in shareholder profit for the six months ending September 30, 2025, with an expected profit of approximately HKD 7.6 million, compared to an estimated profit of HKD 24.8 million for the six months ending September 30, 2024 [1] Financial Performance - The company expects a reduction in profit primarily due to anticipated impairments in receivables, with expected losses of approximately HKD 2.6 million from loans and HKD 4.2 million from trade receivables [1]

Core Viewpoint - The company expects a significant decrease in profit attributable to shareholders for the six months ending September 30, 2025, projecting a profit of no less than approximately 300,000 HKD, compared to 3,040,000 HKD in the same period last year [1] Summary by Relevant Categories Financial Performance - The anticipated profit for the upcoming period is approximately 300,000 HKD, a decline from the previous year's profit of 3,040,000 HKD [1] Cost Factors - The board attributes the profit decline primarily to increased operating costs due to service costs, which have led to a reduction in gross profit [1] - Additionally, there has been an increase in administrative expenses related to employee costs [1]

Core Viewpoint - Novo Nordisk has announced a significant layoff plan and lowered its full-year operating profit forecast shortly after the new CEO took office, indicating a strategic shift in response to market changes, particularly in the weight loss drug sector [2][9]. Group 1: Layoff Plan - Novo Nordisk plans to cut approximately 9,000 jobs globally from a total of 78,400 positions, with around 5,000 layoffs expected in Denmark [5]. - The layoffs will affect various departments, including logistics support and headquarters functions, with communication to impacted employees expected in the coming months [7]. - The company anticipates annual savings of 8 billion Danish kroner (approximately $1.26 billion) by the end of 2026, with these funds redirected towards growth opportunities in diabetes and obesity treatment [7]. Group 2: Financial Impact - The restructuring plan is expected to incur a one-time cost of 8 billion Danish kroner, including impairment charges, with 9 billion Danish kroner in restructuring costs anticipated in Q3 2025 and savings of about 1 billion Danish kroner in Q4 [7]. - Novo Nordisk has revised its operating profit growth forecast for 2025 to a range of 4% to 10%, down from a previous estimate of 10% to 16%, marking the third downward adjustment for the year [9]. - The company has not adjusted its revenue growth forecast, which remains at 8% to 14% for the year [10]. Group 3: Market Context - The company is facing a critical moment as the market share of its weight loss drug Wegovy is declining, and sales growth is slowing, particularly in the U.S. market [9]. - Novo Nordisk's market capitalization has dropped significantly, from a peak of $650 billion to approximately $185 billion, with a loss of $70 billion in market value in July alone [9].

Group 1 - The company, 易和国际控股, expects a significant decrease in net profit for the six months ending June 30, 2025, projecting a profit of between RMB 7 million to RMB 10 million compared to approximately RMB 18.8 million for the same period ending June 30, 2024 [1] - The reduction in profit is primarily attributed to a decrease in revenue, which is linked to weakened market demand for the company's disposable plastic food containers after a notable increase in sales over the past two years [1]